论文部分内容阅读
目的:考察中医药联合新辅助化疗治疗乳腺癌的疗效。方法:125例乳腺癌患者均进行新辅助化疗治疗,随机分为对照组(62例)和观察组(63例),对照组进行新辅助化疗治疗,观察组在进行新辅助化疗治疗基础上给予中药方剂口服治疗,两组均在疗程结束后进行手术治疗,对比分析两组治疗效果、病灶转移率及5年内存活率以及中西医结合对患者生活质量的影响。结果对照组治疗总有效率为66.1%(41/62),显著低于观察组的84.1%(53/63),差异具有统计学意义(P<0.05);对照组病灶转移率为75.8%(47/62),明显高于观察组的23.8%(15/63),差异有统计学意义(P<0.05);对照组5年内生存率为14.5%(9/62),显著低于观察组74.6%(47/63),差异有统计学意义(P<0.05);观察组血象检查各项指标均优于对照组,差异均有统计学意义(P<0.05)。观察组不良反应总例数为26例明显少于对照组的46例,差异有统计学意义(P<0.05);观察组生活质量提高、生活质量稳定的例数优于对照组,差异有统计学意义(P<0.05);观察组生存率优于对照组,差异有统计学意义(P<0.05)。结论:将新辅助化疗与传统中药配合使用对于乳腺癌的治疗效果优于单纯使用新辅助化疗,极大增加了手术彻底切除肿瘤的可能性,具有临床价值,值得进一步推广使用。
Objective: To investigate the efficacy of traditional Chinese medicine combined with neoadjuvant chemotherapy in the treatment of breast cancer. Methods: All 125 breast cancer patients were treated with neoadjuvant chemotherapy. They were randomly divided into control group (62 cases) and observation group (63 cases). The control group received neoadjuvant chemotherapy. The observation group received neoadjuvant chemotherapy Chinese medicine prescription oral treatment, both groups were treated by surgery after the end of treatment, comparative analysis of the two groups of treatment, lesion metastasis and 5-year survival rate and the integration of traditional Chinese and Western medicine on the quality of life of patients. Results The total effective rate of the control group was 66.1% (41/62), significantly lower than that of the observation group (84.1%, 53/63), the difference was statistically significant (P <0.05); the metastasis rate of the control group was 75.8% 47/62), which was significantly higher than that of the observation group (23.8%, 15/63) (P <0.05). The 5-year survival rate of the control group was 14.5% (9/62), which was significantly lower than that of the observation group 74.6% (47/63) respectively, the difference was statistically significant (P <0.05). The indexes of blood test in observation group were better than those in control group (P <0.05). The total number of adverse reactions in observation group was significantly lower than that in control group (26 cases, 46 cases), the difference was statistically significant (P <0.05); the quality of life of observation group was improved, the quality of life was better than that of control group (P <0.05). The survival rate of the observation group was better than that of the control group (P <0.05). Conclusion: The combination of neoadjuvant chemotherapy and traditional Chinese medicine is superior to neoadjuvant chemotherapy alone in the treatment of breast cancer, which greatly increases the possibility of radical resection of the tumor. It is of clinical value and worthy of further promotion.